This website is intended for healthcare professionals only.
Approximately 1 in 3 women will develop uterine fibroids at some point in their life.1 Physical symptoms of uterine fibroids include pain, anaemia, heavy menstrual bleeding, and pelvic discomfort.2 Uterine fibroids also take a psychological toll; 95% of uterine fibroid patients experience psychological distress.3 Ryeqo is a novel gonadotropin-releasing hormone (GnRH) receptor antagonist combined with add-back therapy and is the first combination therapy licensed in the UK for the management of moderate to severe symptoms of uterine fibroids.4
Add-back therapy is a strategy of adding other medication during treatment with GnRH analogues with the aim to limit adverse events.5
Ryeqo is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.4
Prescribing information for Ryeqo can be found here.
For full details of the special warnings and precautions for use associated with Ryeqo, please click here to view the full SmPC.
For more promotional information about Ryeqo, visit www.ryeqo.co.uk
Professor Al-Hendy is the Director of Translational Research from the Department of Obstetrics and Gynecology at the University of Illinois (Chicago, USA). He is the first author of the clinical studies covered in this webinar.
Professor Clark is a Consultant Gynaecologist at the Birmingham Women’s Hospital and an Honorary Professor at the University of Birmingham, Member of the Royal College of Obstetrics and Gynaecology (MRCOG) and Fellow of the Royal College (FRCOG).
Professor Mike Stone is a Consultant Physician in Cardiff and Lead Clinician for adult Metabolic Bone Disease. He heads a long established Fracture Liaison Service, four Bone Clinics each week and the Denosumab Self Injection Program. He is also Director of the Bone Research Unit at University Hospital Llandough.
Watch Professor Ayman Al-Hendy discuss how a novel GnRH antagonist with add-back therapy can benefit patients with moderate to severe symptoms of uterine fibroids. The webinar also covered the results from the LIBERTY trials, the phase III development programme. This webinar was presented live on 27 June 2022.
Watch Professor Justin Clark discuss the current options for the management of women with uterine fibroids in the UK. This webinar was presented live on 27 June 2022.
Watch Professor Mike Stone discuss osteoporosis and bone health for patients with uterine fibroids. This webinar was presented live on 27 June 2022.
Introducing the incidence and symptoms of UFs, focusing on their impact on patient quality of life (QoL).
RYEQO is a GnRH antagonist (relugolix) combined with estradiol and norethisterone acetate Relugolix’s pharmacological inhibition of the GnRH receptors within the body causes a reduction in the production of estradiol, creating an environment that does not support the growth of fibroids.
Join in the discussion and be a part of Hospital Healthcare Europe
Download Hospital Healthcare Europe free app
In official association with
© Cogora 2023
Cogora Limited. 1 Giltspur Street, London EC1A 9DD
Registered in the United Kingdom. Reg. No. 2147432
